Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Will Faraday and Geely Team Up in a Possible Replication of Baidu and Foxconn Manufacturing Partnerships?
Chinese Edtech Startup Huohua Siwei Secures $400 Million in Series E Funding Round
Trending in China: Man Fired for Skipping Work to Mourn Father Gets Billion Views
Impressive New York Trading Debut for Chinese E-Cigarette Maker RLX But Challenges Lie Ahead
Self-Driving Tech Startup Uisee Closes $155 Million Funding Round
Trending in China: Gold Mining Rescue Lights Up Weibo
China Evergrande’s NEV Unit Brings Six Investors On Board to Raise $3.4 Billion
Taiwan’s MediaTek Surpasses Qualcomm as China’s Smartphone Chip Supplier of Choice as U.S. Sanctions Bite
Tencent-Backed Esports Startup VSPN Closes $60 Million Funding
Trending in China: Foreign Medical Students Volunteer for Battle Against Virus in Freezing Northeast
Chinese Telcos Look for More Sympathy Under Biden Administration
Gojek, Tokopedia Explore Holding Company Structure as Merger Talks Move Forward
Carmaker BYD to Raise $3.9 Billion Through New Share Sale
Trending in China: Beijing Skating Now On Ice As Covid Restrictions Imposed
Alibaba’s Jack Ma Reemerges After Long Absence
Chinese Mainland Speeds Up Chip Equipment Buying from ASML
Chinese Edtech Startup Erwan Nets Nearly $100 Million in Series D, E Funding Rounds
Matrix Partners China Raises $1.2 Billion for Flagship Venture Fund
Tesla Denies Final Model Y Pricing Represents Big Cut
Cold-Chain Logistics Startup Xianshenghuo Bags $93 Million in New Funding
Fosun Biotech Unit Henlius Aims to Raise $477 Million in Hong Kong IPO

By Wei Yiyang and Han Wei / Sep 12, 2019 04:15 AM / Business & Tech

Photo: VCG

Photo: VCG

Shanghai Henlius Biotech, a unit of Chinese conglomerate Fosun International, started taking investor orders Wednesday for a Hong Kong initial public offering that could raise as much as HK$3.7 billion ($477 million).

Henlius plans to sell 64.5 million shares, or 12% of its enlarged equity, in a range between HK$49.60 and HK$57.80, according to terms of the deal. The offering will be the first major listing in Hong Kong since July as the city’s market has been rattled by social unrest and pressures from the China-U.S. trade war.

The pre-profit biotech startup has secured four cornerstone investors, including Qatar Investment Authority. The four will invest a combined HK$1 billion in the offering, according to the prospectus.

Henlius completed its last round of fundraising in July 2018, which valued the company at $2.96 billion. The company reported 7.4 million yuan of revenue in 2018, down 78% from the previous year. Net losses expanded 31% to 505 million yuan, according to the prospectus.

Henlius is expected to price the offering Sept. 18 and list on the Hong Kong stock exchange Sept. 25.

China International Capital Corp, Bank of America Corp., CMB International, Fosun Hani Securities and Citigroup Inc. are joint sponsors for the deal.

Contact reporter Han Wei (weihan@caixin.com)

Share this article
Open WeChat and scan the QR code